Central Valley Advisors’s AbbVie ABBV Stock Holding History

Central Valley Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$474K	Buy	1,883 +3	+0.2%	+$645	0.12%	121
2026 Q1	$409K	Hold	1,880	–	–	0.11%	128
2025 Q4	$430K	Hold	1,880	–	–	0.13%	105
2025 Q3	$435K	Buy	1,880 +5	+0.3%	+$1.02K	0.13%	106
2025 Q2	$348K	Sell	1,875 -8	-0.4%	-$1.49K	0.12%	104
2025 Q1	$395K	Sell	1,883 -219	-10%	-$42.6K	0.15%	86
2024 Q4	$374K	Buy	2,102 +2	+0.1%	+$368	0.17%	99
2024 Q3	$415K	Sell	2,100 -3	-0.1%	-$560	0.23%	80
2024 Q2	$361K	Hold	2,103	–	–	0.15%	81
2024 Q1	$383K	Sell	2,103 -10	-0.5%	-$1.72K	0.2%	93
2023 Q4	$327K	Buy	+2,113	New	+$308K	0.19%	107

Other funds holding ABBV

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

ECSS

Eurizon Capital SGR SpA Milan $37.3B AUM

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Central Valley Advisors's ABBV Position: Q2 2026 in Review

Central Valley Advisors increased its AbbVie (ABBV) stake by 0.16% in Q2 2026, buying an estimated $645 and bringing the position to 1,883 shares worth $474K. The position accounts for 0.12% of the portfolio, ranked #121.

Central Valley Advisors first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Central Valley Advisors held 1,883 shares of AbbVie worth $474K as of Q2 2026.
Central Valley Advisors bought 3 AbbVie shares in Q2 2026, an estimated $645.
AbbVie made up 0.12% of Central Valley Advisors's portfolio in Q2 2026, its #121 holding.
Central Valley Advisors first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Central Valley Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.